EP
HUMA icon

Eudaimonia Partners’s Humacyte HUMA Stock Holding History

Eudaimonia Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,302
Closed -$73K – 409
2022
Q1 		$73K Buy
+10,302
New +$60K 0.01% 398
2021
Q3 		$291K Sell
25,038
-1,656
-6% -$18.9K 0.05% 314
2021
Q2 		$272K Buy
+26,694
New +$275K 0.05% 319

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Eudaimonia Partners's HUMA Position: Q2 2022 in Review

Eudaimonia Partners sold out of Humacyte (HUMA) in Q2 2022, closing a stake of 10,302 shares — an estimated $73K sold.

Eudaimonia Partners first reported a position in HUMA in Q2 2021 and held it in 3 quarters. The position peaked at $291K in Q3 2021. 78 funds tracked by Wall St. Rank hold HUMA as of Q2 2022.

  • Eudaimonia Partners reported no remaining Humacyte position as of Q2 2022 after selling out during the quarter.
  • Eudaimonia Partners sold 10,302 Humacyte shares in Q2 2022, an estimated $73K.
  • Eudaimonia Partners first reported a position in Humacyte in Q2 2021 and held it in 3 quarters.
  • Eudaimonia Partners's Humacyte position peaked at $291K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Humacyte as of Q2 2022.

Based on Eudaimonia Partners's 13F filing for Q2 2022, filed 9 Aug 2022.